BCL2 and diffuse large B-cell lymphoma: The positive rates in our cohort were lower than those from previous studies, with positive expression of MYC, BCL2, double expression of MYC and BCL2, p53, and CD5 in DLBCL at 33%, 53%, 50%, 22%, and 22%, respectively.24, 25